Future directions in chimeric antigen receptor T cell therapy

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · see citing works

Current concepts in the diagnosis and management of cytokine release syndrome.

Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · see citing works

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,484 · see citing works

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · see citing works

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · see citing works

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works

Toxicities of chimeric antigen receptor T cells: recognition and management

Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,411 · see citing works

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,251 · see citing works

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

Maude, S. L., Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 753 · see citing works

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L., Finney, O. C., Smithers, H. M., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 751 · see citing works

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 699 · see citing works

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

Scholler, J., Brady, T., Binder-Scholl, G. K., Hwang, W., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M. D., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 651 · see citing works

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 566 · see citing works

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 524 · see citing works

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Gill, S. I., Tasian, S. K., Ruella, M., Shestova, O. E., Li, Y., Porter, D. L., Carroll, M. P., Danet-Desnoyers, G. A., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 488 · see citing works

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A., Dentchev, T., Thekkat, P. U., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 452 · see citing works

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K. M., Gryder, B. E., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 431 · see citing works

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

Kenderian, S. S., Ruella, M., Shestova, O. E., Klichinsky, M., Aikawa, V., Morrissette, J. J. D., Scholler, J., Song, D., Porter, D., Carroll, M. P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 429 · see citing works

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

Caruso, H. G., Hurton, L. V., Najjar, A. M., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K. C., Singh, H., Huls, H. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 399 · see citing works

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

Mardiros, A., Santos, C. D., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., Hoffman, L., Aguilar, B., Chang, W.-C., Bretzlaff, W. S., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474056 · Cited by 373 · see citing works

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

Gargett, T., & Brown, M. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00235 · Cited by 371 · see citing works

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232

Borowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., Nachman, J. B., Carroll, A. J., Heerema, N. A., Gastier, J. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633685 · Cited by 362 · see citing works

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

Gargett, T., Yu, W., Dotti, G., Yvon, E. S., Christo, S. N., Hayball, J. D., Lewis, I. D., Brenner, M. K., & Brown, M. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.63 · Cited by 356 · see citing works

Chimeric Antigen Receptor Therapy for Cancer

Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 350 · see citing works

CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy

Scheuermann, R. H., & Racila, E. V. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509059636 · Cited by 323 · see citing works

Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 323 · see citing works

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

Pizzitola, I., Anjos‐Afonso, F., Rouault‐Pierre, K., Lassailly, F., Tettamanti, S., Spinelli, O., Biondi, A., Biagi, E., & Bonnet, D. A. (2014) · Leukemia · doi:10.1038/leu.2014.62 · Cited by 287 · see citing works

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

Cartellieri, M., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Ehninger, A., Bonin, M. V., Bejestani, E. P., Ehninger, G., & Bachmann, M. P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.61 · Cited by 247 · see citing works

Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection

Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P. R., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 239 · see citing works

Chimeric antigen receptor T-cell therapy for solid tumors

Newick, K., Moon, E. K., & Albelda, S. Μ. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.6 · Cited by 237 · see citing works

The ABCs of artificial antigen presentation

Kim, J. V., Latouche, J., Rivière, I., & Sadelain, M. (2004) · Nature Biotechnology · doi:10.1038/nbt955 · Cited by 191 · see citing works

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

Maude, S. L., Teachey, D. T., Rheingold, S. R., Shaw, P. A., Aplenc, R., Barrett, D. M., Barker, C. S., Callahan, C. A., Frey, N. V., Nazimuddin, F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3011 · Cited by 149 · see citing works

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

Beatty, G. L., & O’Hara, M. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.010 · Cited by 131 · see citing works

Large-Scale Production of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation*

Levine, B. L., Cotte, J., SMALL, C. C., Carroll, R. G., Riley, J. L., Bernstein, W. B., Epps, D. E. V., Hardwick, R. A., & June, C. H. (1998) · Journal of Hematotherapy · doi:10.1089/scd.1.1998.7.437 · Cited by 125 · see citing works

Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia

Barrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 111 · see citing works

Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis

Lee, S. C.-W., Miller, S., Hyland, C. D., Kauppi, M., Lebois, M., Rago, L. D., Metcalf, D., Kinkel, S., Josefsson, E. C., Blewitt, M. E., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615898 · Cited by 105 · see citing works

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

O'Hear, C. E., Heiber, J. F., Schubert, I. A., Fey, G. H., & Geiger, T. L. (2014) · Haematologica · doi:10.3324/haematol.2014.112748 · Cited by 105 · see citing works

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia

Bonifant, C. L., Szöőr, Á., Torres, D., Joseph, N. P., Velasquez, M. P., Iwahori, K., Gaikwad, A. S., Nguyen, P., Arber, C., Song, X., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.116 · Cited by 83 · see citing works

4-1BB Chimeric Antigen Receptors

Campana, D., Schwarz, H., & Imai, C. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000028 · Cited by 54 · see citing works

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Lee, D. W., Stetler‐Stevenson, M., Yuan, C. M., Fry, T. J., Shah, N. N., Delbrook, C., Yates, B., Zhang, H., Zhang, L., Kochenderfer, J. N., et al. (2015) · Blood · doi:10.1182/blood.v126.23.684.684 · Cited by 51 · see citing works

Nonviral RNA Transfection to Transiently Modify T Cells with Chimeric Antigen Receptors for Adoptive Therapy

Riët, T., Holzinger, A., Dörrie, J., Schaft, N., Schuler, G., & Abken, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_12 · Cited by 50 · see citing works

Antibody therapy for acute myeloid leukaemia

Gasiorowski, R., Clark, G. J., Bradstock, K. F., & Hart, D. N. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12691 · Cited by 48 · see citing works

Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL)

Reismüller, B., Peters, C., Dworzak, M. N., Pötschger, U., Urban, C. E., Meister, B., Schmitt, K., Dieckmann, K. U., Gadner, H., Attarbaschi, A., et al. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318290c3d6 · Cited by 44 · see citing works

Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).

Frey, N. V., Shaw, P. A., Hexner, E. O., Gill, S. I., Marcucci, K. T., Luger, S. M., Mangan, J. K., Grupp, S. A., Maude, S. L., Ericson, S. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7002 · Cited by 42 · see citing works

Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL.

Park, J. H., Rivière, I., Wang, X., Purdon, T. J., Sadelain, M., & Brentjens, R. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7003 · Cited by 30 · see citing works

CD123 redirected multiple virus-specific T cells for acute myeloid leukemia

Zhou, L., Liu, X., Wang, X., Sun, Z., & Song, X.-T. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.12.003 · Cited by 15 · see citing works

Clinical use of lentiviral vectors

Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930 · see citing works

Potential targeting of B7‐H4 for the treatment of cancer

Podojil, J. R., & Miller, S. D. (2017) · Immunological Reviews · doi:10.1111/imr.12530 · Cited by 160 · see citing works

Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia

Heikamp, E., & Pui, C. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.07.039 · Cited by 51 · see citing works

New targeted therapies for relapsed pediatric acute lymphoblastic leukemia

Pierro, J., Hogan, L. E., Bhatla, T., & Carroll, W. L. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1347507 · Cited by 44 · see citing works

Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges

Jasinski, S., Reyes, F. A. D. L., Yametti, G. C., Pierro, J., Raetz, E. A., & Carroll, W. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00413-3 · Cited by 42 · see citing works

Development of CAR T Cell Therapy in Children—A Comprehensive Overview

Boettcher, M., Joechner, A., Li, Z., Yang, S. F., & Schlegel, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082158 · Cited by 42 · see citing works

Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies

Cherian, S., & Stetler‐Stevenson, M. (2018) · Current Protocols in Cytometry · doi:10.1002/cpcy.44 · Cited by 34 · see citing works

CReVIS-Seq: A highly accurate and multiplexable method for genome-wide mapping of lentiviral integration sites

Kim, H. S., Hwang, G., Lee, H. K., Bae, T., Park, S.-H., Kim, Y. J., Lee, S., Park, J.-H., Bae, S., & Hur, J. K. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.012 · Cited by 32 · see citing works

Cellular therapies: Day by day, all the way

Atilla, E., Kılıç, P., & Gürman, G. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.04.019 · Cited by 25 · see citing works

Progress in adult ALL: incorporation of new agents to frontline treatment

Leonard, J. T., & Stock, W. (2017) · Hematology · doi:10.1182/asheducation-2017.1.28 · Cited by 16 · see citing works

Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia

Myers, R. M., Dolan, J. G., & Teachey, D. T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1828067 · Cited by 16 · see citing works

Targeted gene delivery systems for T-cell engineering

Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 10 · see citing works

T cell modulation in immunotherapy for hematological malignancies

Lin, C., Chen, S., & Li, Y. (2017) · Cell Biology and Toxicology · doi:10.1007/s10565-017-9397-6 · Cited by 7 · see citing works

Avances en el tratamiento de la leucemia aguda linfoblástica del adulto

Ribera, J., & Vives, S. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.03.027 · Cited by 3 · see citing works

Acute lymphoblastic leukemia in adults: Steps ahead

Ribera, J., & Vives, S. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.06.039 · Cited by 2 · see citing works

Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing

Huynh, V., Laetsch, T. W., Schore, R. J., Gaynon, P. S., & O'Brien, M. M. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1397073 · Cited by 2 · see citing works

Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches

Shin, Y. H., Tian, X., Park, J. J., Kim, G. Y., Aboujaoude, E., & Sturgill, M. G. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211039238 · Cited by 2 · see citing works

Cancer Immunotherapy in Children

Hirabayashi, K., Dotti, G., & Savoldo, B. (2020) · doi:10.1093/med/9780198797210.003.0008 · Cited by 1 · see citing works

CD19‐Targeted chimeric antigen receptor‐modified T‐cell immunotherapy for B‐cell malignancies

Turtle, C. J., Riddell, S., & Maloney, D. G. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.392 · Cited by 78 · see citing works

Early Clinical Outcomes of Chimeric Antigen Receptor Modified T Cells and the Generation of "Armored" CAR T Cells for Future Applications to Cancer Immunotherapy

Davila, M. L., & Brentjens, R. J. (2013) · AACR Education book · doi:10.1158/aacr.edb-13-7842

Chimeric antigen receptor T-cell therapy for ALL

Maude, S. L., Shpall, E. J., & Grupp, S. A. (2014) · Hematology · doi:10.1182/asheducation-2014.1.559 · Cited by 68 · see citing works

Chimeric Antigen Receptor T‐Cell Therapy Clinical Results in Pediatric and Young Adult B‐ALL

DiNofia, A. M., & Maude, S. L. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000279 · Cited by 28 · see citing works

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

Geyer, M. B., & Brentjens, R. J. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.07.003 · Cited by 92 · see citing works